Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients
M. Milano(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Valenti(University of Verona), Stefano Romeo(Karolinska University Hospital), Anna Ludovica Fracanzani(University of Milan), Massimo Colombo(University of Milan), Raffaele De Francesco(Istituto Nazionale Genetica Molecolare), Marco Maggioni(University of Milan), Felix Stickel(University of Bern), Janett Fischer(Leipzig University), Roberta D’Ambrosio(University of Southern California), Alessio Aghemo, Jochen Hampe(Technische Universität Dresden), Thomas Berg(University Hospital Leipzig), Silvia Fargion(Institute of Clinical and Experimental Medicine), Rosellina Margherita Mancina(University of Gothenburg), Paola Dongiovanni(Ospedale Maggiore), Stella De Nicola(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 58
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877